CY1108217T1 - Μεθοδος χορηγησης βουπρενορφινης για τη θεραπεια της καταθλιψης - Google Patents

Μεθοδος χορηγησης βουπρενορφινης για τη θεραπεια της καταθλιψης

Info

Publication number
CY1108217T1
CY1108217T1 CY20081100780T CY081100780T CY1108217T1 CY 1108217 T1 CY1108217 T1 CY 1108217T1 CY 20081100780 T CY20081100780 T CY 20081100780T CY 081100780 T CY081100780 T CY 081100780T CY 1108217 T1 CY1108217 T1 CY 1108217T1
Authority
CY
Cyprus
Prior art keywords
depression
buprenorfine
administration
buprenorphine
department treatment
Prior art date
Application number
CY20081100780T
Other languages
English (en)
Inventor
Robert F Kaiko
Ramiro Sanchez
Original Assignee
Euro-Celtique S.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Euro-Celtique S.A. filed Critical Euro-Celtique S.A.
Publication of CY1108217T1 publication Critical patent/CY1108217T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Dermatology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Emergency Medicine (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Saccharide Compounds (AREA)

Abstract

Εδώ περιγράφεται μια μέθοδος για τη θεραπεία της κατάθλιψης με τη χρησιμοποίηση διαδερμικής χορήγησης βουπρενορφίνης. Σε μια ενσωμάτωση, η μέθοδος χρησιμοποιεί διαδερμικά επιθέματα περιέχοντα βουπρενορφίνη, που κατά προτίμηση κλιμακώνουν επαυξητικά τη δόση της βουπρενορφίνης σε ένα επίπεδο όπου ανακουφίζονται ένα ή περισσότερα συμπτώματα της κατάθλιψης. Η μέθοδος είναι ιδιαίτερα κατάλληλη για ασθενείς που πάσχουν από ανθεκτική κατάθλιψη, ή για ασθενείς που πάσχουν από αμφότερα κατάθλιψη και πόνο.
CY20081100780T 2002-03-20 2008-07-28 Μεθοδος χορηγησης βουπρενορφινης για τη θεραπεια της καταθλιψης CY1108217T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US36635802P 2002-03-20 2002-03-20
EP03721427A EP1485051B1 (en) 2002-03-20 2003-03-20 Method of administering buprenorphine to treat depression

Publications (1)

Publication Number Publication Date
CY1108217T1 true CY1108217T1 (el) 2014-02-12

Family

ID=28454789

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20081100780T CY1108217T1 (el) 2002-03-20 2008-07-28 Μεθοδος χορηγησης βουπρενορφινης για τη θεραπεια της καταθλιψης

Country Status (12)

Country Link
US (1) US20030181475A1 (el)
EP (1) EP1485051B1 (el)
JP (1) JP2005528359A (el)
AT (1) ATE394097T1 (el)
AU (1) AU2003224742A1 (el)
CY (1) CY1108217T1 (el)
DE (1) DE60320770D1 (el)
DK (1) DK1485051T3 (el)
ES (1) ES2305457T3 (el)
PT (1) PT1485051E (el)
SI (1) SI1485051T1 (el)
WO (1) WO2003079945A1 (el)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5968547A (en) * 1997-02-24 1999-10-19 Euro-Celtique, S.A. Method of providing sustained analgesia with buprenorphine
EP1913938A1 (en) * 2002-12-13 2008-04-23 Euro-Celtique S.A. Transdermal buprenorphine dosage regimen for analgesia
AU2003297073A1 (en) 2002-12-13 2004-07-09 Euro-Celtique S.A. Transdermal buprenorphine dosage regimen for analgesia
CA2522529C (en) 2003-04-30 2015-10-20 Purdue Pharma L.P. Tamper resistant transdermal dosage form
US8790689B2 (en) 2003-04-30 2014-07-29 Purdue Pharma L.P. Tamper resistant transdermal dosage form
DK1646328T3 (da) 2003-07-25 2008-02-04 Euro Celtique Sa Behandling af afhængighedsophör
DE10340428B4 (de) * 2003-09-02 2015-02-12 Acino Ag Opioides Analgetikum enthaltende transdermale Formulierung
FR2865650B1 (fr) * 2004-01-30 2008-06-13 Biocortech Utilisation du 14,15 dihydro 20,21-dinoreburnamenin14-ol pour traiter et/ou prevenir les depressions majeures et les desordres du cycle veille-sommeil
DE102004045599A1 (de) * 2004-09-17 2006-03-23 Grünenthal GmbH System zur sequentiellen, transdermalen Verabreichung von systemisch wirksamen Substanzen
DE102005007859A1 (de) * 2005-02-21 2006-08-24 Lts Lohmann Therapie-Systeme Ag Vefahren für eine medikamentöse Kombinations-Behandlung, sowie hierfür geeignete Arzneimittel-Kombinationen
DE102006011340A1 (de) * 2006-03-09 2007-09-20 Grünenthal GmbH Wirkstoffhaltige Pflaster mit verbesserter Handhabung
HUE043963T2 (hu) 2009-12-04 2019-09-30 Alkermes Pharma Ireland Ltd Morfinán származékok gyógyszer-túladagolás kezelésére
AU2011293502B2 (en) 2010-08-23 2015-03-19 Alkermes Pharma Ireland Limited Methods for treating antipsychotic-induced weight gain
US10813925B2 (en) 2011-09-19 2020-10-27 Carmel—Haifa University Economic Corporation Ltd. Buprenorphine for the treatment of acute suicidality
US9211293B2 (en) 2011-12-15 2015-12-15 Alkermes Pharma Ireland Limited Opioid agonist antagonist combinations
EP2790703B1 (en) * 2011-12-15 2019-06-12 Alkermes Pharma Ireland Limited Samidorphan (alks 33) in combination with opioid agonists
EA030609B8 (ru) 2011-12-15 2018-10-31 Алкермес Фарма Айэленд Лимитед Композиции бупренорфина и антагонистов мю-опиоидных рецепторов
US10195191B2 (en) 2011-12-15 2019-02-05 Alkermes Pharma Ireland Limited Opioid agonist antagonist combinations
EP3004114B1 (en) 2013-05-24 2019-12-25 Alkermes Pharma Ireland Limited Morphan and morphinan analogues, and methods of use
EP3003311A2 (en) 2013-05-24 2016-04-13 Alkermes Pharma Ireland Limited Methods for treating depressive symptoms
CA2933733A1 (en) * 2013-12-20 2015-06-25 Connie Sanchez Morillo Use of an opioid receptor antagonist with kappa-activity and vortioxetine for treatment of depressive disorder with melancholic features
EP4243768A1 (en) 2020-11-12 2023-09-20 Alkermes Pharma Ireland Limited Immediate release multilayer tablet

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4806341A (en) * 1985-02-25 1989-02-21 Rutgers, The State University Of New Jersey Transdermal absorption dosage unit for narcotic analgesics and antagonists and process for administration
US5026556A (en) * 1988-11-10 1991-06-25 Norwich Eaton Pharmaceuticals, Inc. Compositions for the transdermal delivery of pharmaceutical actives
US4956171A (en) * 1989-07-21 1990-09-11 Paco Pharmaceutical Services, Inc. Transdermal drug delivery using a dual permeation enhancer and method of performing the same
US5240711A (en) * 1989-11-29 1993-08-31 Lts Lohmann Therapie-Systeme Gmbh & Co. Kg Transdermal therapeutic system comprising as active component buprenorphine
AU637496B2 (en) * 1990-04-24 1993-05-27 Teijin Limited Plaster
US5069909A (en) * 1990-06-20 1991-12-03 Cygnus Therapeutic Systems Transdermal administration of buprenorphine
US5512593A (en) * 1993-03-02 1996-04-30 John S. Nagle Composition and method of treating depression using natoxone or naltrexone in combination with a serotonin reuptake inhibitor
US5613958A (en) * 1993-05-12 1997-03-25 Pp Holdings Inc. Transdermal delivery systems for the modulated administration of drugs
DK0889723T3 (da) * 1996-03-25 2002-09-23 Lohmann Therapie Syst Lts Transdermalt terapeutisk system med ringe tykkelse af administreringsareal og stor fleksibilitet samt fremgangsmåde til fremstilling heraf
US6787149B1 (en) * 1996-12-12 2004-09-07 El Khoury And Stein Ltd. Topical application of opioid analgesic drugs such as morphine
US5968547A (en) * 1997-02-24 1999-10-19 Euro-Celtique, S.A. Method of providing sustained analgesia with buprenorphine
US5900420A (en) * 1997-06-19 1999-05-04 Cole; William L. Method for treating chronic fatigue syndrome and fibromyalgia with buprenorphine
DE19738855C2 (de) * 1997-09-05 2001-01-04 Lohmann Therapie Syst Lts Transdermales therapeutisches System mit haftklebender Reservoirschicht und unidirektional elastischer Rückschicht
DE19746191C2 (de) * 1997-10-18 2000-05-18 Lohmann Therapie Syst Lts Verfahren zur Anwendung eines Wirkstoff enthaltenden Pflasters zur Bekämpfung oder Linderung einer Sucht
WO1999045906A1 (en) * 1998-03-09 1999-09-16 Trustees Of Tufts College Treatment of compulsive behaviours in man and animals
DE19840758A1 (de) * 1998-09-07 2000-03-09 Liedtke Pharmed Gmbh Systemische Therapie von Schmerz- und depressiver Befindlichkeit

Also Published As

Publication number Publication date
ATE394097T1 (de) 2008-05-15
SI1485051T1 (sl) 2008-10-31
JP2005528359A (ja) 2005-09-22
EP1485051A1 (en) 2004-12-15
PT1485051E (pt) 2008-07-09
DE60320770D1 (de) 2008-06-19
EP1485051A4 (en) 2006-05-24
DK1485051T3 (da) 2008-09-08
US20030181475A1 (en) 2003-09-25
AU2003224742A1 (en) 2003-10-08
WO2003079945A1 (en) 2003-10-02
EP1485051B1 (en) 2008-05-07
ES2305457T3 (es) 2008-11-01

Similar Documents

Publication Publication Date Title
CY1108217T1 (el) Μεθοδος χορηγησης βουπρενορφινης για τη θεραπεια της καταθλιψης
IS2630B (is) Meðferð á fráhvarfseinkennum
ATE380548T1 (de) Verwendung von p53 inhibitoren zur behandlung von nebenerscheinungen bei der krebstherapie
MY151032A (en) Treatment of tnf? related disorders
ATE405272T1 (de) Behandlung von t-zellen-lymphom mittels 10- propargyl-10-deazaaminopterin
DE60322102D1 (de) Transdermales buprenorphin-dosierschema zwecks schmerzstillung
IS8186A (is) Meðferð fyrir uppskurð á verkjum eftir uppskurð
DE602004018944D1 (de) Verwendung von abführmittel zur behandlung des reizdarmsyndroms
ATE453402T1 (de) Verwendung von serp-1 in kombination mit einem immunosuppressor zur behandlung von arthritis
BR0307022A (pt) Método de tratamento de um paciente que precisa de analgesia
SE9902597D0 (sv) New use
ATE484280T1 (de) Verwendung der kombination aus temozolomid und tnf-alpha zur behandlung von glioblastoma
ATE345805T1 (de) Calciumtrifluoracetat mit zytotoxischer wirkung
WO2003068156A3 (en) Methods for treating or inhibiting sick building syndrome, post-lyme disease syndrome, and/or chronic fatigue syndrome
EP1795189A3 (en) Method of administering buprenorphine to treat depression
WO2005102367A3 (en) Coadministration of radiation, efaproxiral sodium, and supplemental oxygen for the treatment of cancer
DE60316927D1 (de) Verwendung von devazepide als schmerzmittel
CY1113524T1 (el) Μεθοδοι χαμηλης δοσης για τη θεραπεια διαταραχων στις οποιες η δραστικοτητα του tnfα ειναι επιβλαβης
DE60121449D1 (de) Behandlung von hepatitis c mit thymosin und pegyliertem interferon
EA200000514A1 (ru) Способ лечения эректильной дисфункции